Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms

Background: Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient po...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutic advances in gastroenterology 2019-06, Vol.12, p.1756284819857358-1756284819857358
Hauptverfasser: Serrano-Falcón, Blanca, Delgado-Aros, Sílvia, Mearin, Fermín, Ciriza de los Ríos, Constanza, Serra, Jordi, Mínguez, Miguel, Montoro Huguet, Miguel, Perelló, Antonia, Santander, Cecilio, Pérez Aisa, Ángeles, Bañón-Rodríguez, Inmaculada, Rey, Enrique
Format: Artikel
Sprache:eng
Schlagworte:
Constipation
Gastroenterology
Irritable bowel syndrome
Original Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient population. Methods: In this open-label phase IIIb study, patients with moderate-to-severe IBS-C received linaclotide 290 μg once daily for 12 weeks. The primary endpoint was clinical response at week 12, defined as >30% reduction in IBS symptom severity score (IBS-SSS) or IBS-SSS
ISSN:1756-2848
1756-283X
1756-2848
DOI:10.1177/1756284819857358